Kevin Balthaser - Feb 1, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Employee Stock Option (Right to Buy)	Award	$0	+207K	$0.00	207K	Feb 1, 2024	Common Stock	207K	$1.20	Direct	F1
transaction	ACRS	Restricted Stock Units	Award	$0	+59K	$0.00	59K	Feb 1, 2024	Common Stock	59K		Direct	F2, F3
transaction	ACRS	Restricted Stock Units	Award	$0	+148K	$0.00	148K	Feb 1, 2024	Common Stock	148K		Direct	F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F3	The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4	50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.